Genprex Inc (NASDAQ:GNPX) has been given a consensus broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation. Genprex’s rating score has declined by 50% from 90 days ago as a result of various analysts’ ratings changes.
Zacks has also given Genprex an industry rank of 86 out of 256 based on the ratings given to its competitors.
GNPX has been the subject of several analyst reports. ValuEngine raised shares of Genprex from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Genprex from a “sell” rating to a “hold” rating in a report on Tuesday, June 18th. Finally, Noble Financial assumed coverage on shares of Genprex in a report on Monday, April 29th. They set an “outperform” rating and a $5.00 price objective on the stock.
Genprex (NASDAQ:GNPX) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.09. On average, equities research analysts anticipate that Genprex will post -0.87 EPS for the current year.
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
See Also: What is a Lock-Up Period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.